Previous 10 | Next 10 |
2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...
2024-05-30 09:00:00 ET Summary Markets spooked by the Fed's language on inflation progress, causing uncertainty on rate cuts. Dividend Harvesting Portfolio retraces slightly but still generates respectable dividend income. Portfolio composition shows diversification and focus ...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
2024-05-29 17:44:01 ET Summary ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overcome resistance to other standard-of-care treatments...
2024-05-29 17:11:50 ET More on BridgeBio Pharma BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident Cantor picks 14 undervalued biotech stocks worth a second look BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of ...
2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...
2024-05-29 10:07:00 ET As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with billions of dollars devoted to research and development, it...
2024-05-28 13:31:54 ET Summary On April 26, Gilead Sciences published financial results for the first quarter of 2024, which were better than I expected. So, total sales of oncology drugs amounted to $789 million, up about 18% yearly thanks to strong sales of Trodelvy. On May ...
2024-05-28 13:00:00 ET Summary Asif Suria focuses on risk rather than reward with event-driven strategies. Interest in commodities, particularly copper, oil, and gold, which have been performing well. Scaling back on tech stocks and exploring opportunities in merger arbitrage,...
2024-05-28 07:05:00 ET Summary There are numerous stocks with safe and attractive high yields. There are several of them that we are avoiding right now, including a few that we recently sold. We share five that we are avoiding right now and also list a few that we are buying. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...